| mBC | Metastatic breast cancer |
| HR+ | Hormone receptor-positive |
| HER2− | Human epidermal growth factor receptor 2-negative |
| PET | Positron emission tomography |
| 18F-FES | 16α-18F-fluoro-17β-fluoroestradiol |
| FDA | Food and Drug Administration |
| CDK4/6i | Cyclin-dependent kinase 4/6 inhibitors |
| CT | Computed tomography |
| ET | Endocrine therapy |
| SUV | Standardized uptake value |